Stock futures dipped as Brent crude stayed above $98/barrel. ZIM rose 6% after Hapag-Lloyd revised its $4.2B acquisition plan with Israeli officials. ASML gained 2% as Samsung, TSMC, and Intel advance adoption of High-NA EUV equipment. Novartis plummeted 13% due to a failed late-stage trial for del-desiran, triggering broader biotech losses including DYN (-30%) and SRPT (-11%).